ライフサイエンスコーパス: OS

1 OS after (223)Ra (median, 15.2 mo) was reduced to 7.3 mo

2 OS and COS were combined with phosphoric acid (1.6 mM an

3 OS and DFS did not differ significantly between the grou

4 OS for patients with stage I-II NLPHL was excellent afte

5 OS from LT was 12.5 years, with a median time to LT of 7

6 OS was significantly better than in HCC-PVTT patients re

7 OSs obtained from 2 of the 75 participants in the first

8 HR], 0.43; 95% CI, 0.28 to 0.64; P < .0001), OS (HR, 1.08; 95% CI, 0.72 to 1.61; P = .71), and TWP (H

9 asures (FDI: r = 0.74, F = 28.81, P < 0.001; OS length: r = 0.65; F = 7.94, P < 0.008; photoreceptor

10 For HCT after 2008, OS according to donor was 100% for MFDs and UDs and 85%

11 cidate the isomeric structures of the MW 212 OSs.

12 ortality and greater potential to improve 5Y-OS.

13 with regards to 5-year overall survival (5Y-OS) compared with breast, prostate, uterine, and ovarian

14 enges of identifying patients that derive an OS benefit from bevacizumab.

15 univariable analyses and subgroup analyses, OS and the cumulative incidence of relapse of patients w

16 nce interval [CI], 0.50-0.80; P < 0.001) and OS (HR, 0.67; 95% CI, 0.50-0.90; P = 0.007) and higher s

17 (HR, 1.74; 95% CI, 1.19-2.54; P = .004) and OS (HR, 2.02; 95% CI, 1.57-2.60; P < .001).

18 ll, with DFS of 66.1% v 65.5% (HR, 1.02) and OS of 73.5% v 73.7% (HR, 1.19) in arms 1 and 2, respecti

19 the training cohort for DFS (p = 0.025) and OS (p = 0.002), external validation using these cutoffs

20 lar 5-year EFS (49.0% v 45.1%; P = .534) and OS (65.0% v 61.9%; P = .613) to those unexposed; however

21 cPFS and OS results were consistent irrespective of PI3K/AKT/PTEN

22 OR, CR and OS rates by day 100 were 86.7, 53.3 and 86.7%, respectiv

23 Genomic correlates of CTR and OS in IU-CRLM have not been previously explored.

24 wsuits amongst private practice dentists and OS has not been addressed.

25 ollow-up of 52 months, the projected DFS and OS probabilities were 0.55 and 0.47 (log-rank P = .323)

26 Adjusted hazard ratios for DFS and OS were, respectively, 1.12 (95% CI, 0.98 to 1.50; P = .

27 t a median follow-up of 58.7 months, EFS and OS were 84.5% and 87.0%, respectively, and EFS was 100%

28 Five-year CILP, EFS, and OS rates for patients in A3973 with incomplete resection

29 adiotherapy (n = 323), 5-year CILP, EFS, and OS rates were 11.2% +/- 1.8%, 56.2% +/- 3.4%, and 68.4%

30 astatic pattern were correlated with MFS and OS using univariable Cox proportional hazard models.

31 ere calculated based on the observed MFS and OS.

32 ax) predicted a significantly longer PFS and OS (both P <= 0.03; univariate survival analyses) wherea

33 n independent predictor for improved PFS and OS and can be proposed as the standardized criterion of

34 to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.

35 Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respective

36 and was an independent predictor of PFS and OS on multivariable analysis.

37 dependently associated with inferior PFS and OS were as follows: TP53 aberration, prior treatment, be

38 week 8 was associated with favorable PFS and OS, while having prior episodes of PD and the time from

39 maintenance associates with improved PFS and OS.

40 PS as independently associated with PFS and OS.

41 R2-targeting resulted in significant RFS and OS benefits.

42 ath was reduced by 42% in the tucatinib arm (OS HR, 0.58; 95% CI, 0.40 to 0.85; P = .005).

43 OS activity based on a kinetic bias between OS and CS assay readout times.

44 ly evaluate the proteome shifts exhibited by OS cells in response to hypoxia.

45 the protein profiles of two isogenic canine OS cell lines, POS (low metastatic) and HMPOS (highly me

46 principle, variability in levels of cervical OS has the potential to influence the likelihood of conv

47 The rates of cumulative OS in the first, second, and third years were 95.2%, 91.

48 ming P/rds generated abundant high-curvature OS membranes, which were improperly but specifically org

49 % CI, 1.84 to 4.69; P < .001), and decreased OS (HR, 1.97; 95% CI, 1.17 to 3.30; P = .01) compared wi

50 ependently associated with worse OS and DFS (OS: hazard ratio [HR], 0.98; confidence interval [CI], 0

51 ith NA substitutions previously found during OS and ZAN selection in avian influenza viruses (AIVs) o

52 king PRCD display disoriented and dysmorphic OS disc membranes.

53 ltiple trials or cohorts, which reported EFS/OS results by pCR in patients with early-stage TNBC.

54 to, but more severe than, that in the ERbeta(OS-/-)mice.

55 Furthermore, in the left eye (OS), a vitreous thickening was observed in the nasal sec

56 es where AUC increased by 5.7% and 13.0% for OS and RFS, respectively.

57 d prognosis (HR 0.50 (0.31-0.80)p= 0.004 for OS, 0.60 (0.40-0.90)p = 0.014 for DFS).

58 for bRFS and 0.94 (95% CI, 0.68 to 1.30) for OS.

59 or adverse survival (HR 2.36 (1.54-3.61) for OS, 2.37 (1.47-3.80) for DFS (both p < 0.001), supersedi

60 Multivariable Cox analysis for OS was performed.

61 0.027 and P = 0.0003, respectively) and for OS (P = 0.0007 and P = 0.0095, respectively).

62 nd gain 1q21 conferred an adverse factor for OS and hemEFS with DD, whereas translocation t(11;14) wa

63 004) were independent predictive factors for OS.

64 pper boundary of 95% confidence interval for OS.

65 ictive value of (64)Cu-DOTATATE SUV(max) for OS and PFS.

66 ARID1A mutation was associated with greater OS (hazard ratio [HR]: 3.1; 95% CI: 1.2, 10; P = .01).

67 Patients with metastatic disease had OS rates of 77.8% and 22.2% at 1- and 3- years.

68 Higher OS activity for transgene-produced FVIII-SQ was observed

69 Consistent with the observed higher OS in patients with TERT-low/non-ALT tumors, continuous

70 mbin formation, which may explain the higher OS activity based on a kinetic bias between OS and CS as

71 sites (facial averages) of women with higher OS as more attractive, healthier, younger, and less symm

72 However, OS was significantly decreased only in the latter group

73 Among >=75% compliant patients, however, OS at 3 y was significantly improved in the immunomodula

74 om the weighted linear regression of log(HR)-OS on log(HR)-EFS.

75 so found that JAB1 is overexpressed in human OS and correlates with a poor prognosis.

76 addition of BT did not significantly improve OS (HR, 1.03 [95% CI, 0.78 to 1.36]).

77 Improved OS and lower relapse risk were observed following TBI pl

78 ght have led to early diagnosis and improved OS, and increased investment in health care resources in

79 The addition of ADT to EBRT improved OS (hazard ratio [HR], 0.71 [95% CI, 0.62 to 0.81]), whe

80 rk meta-analysis, EBRT plus ADT had improved OS compared with EBRT plus BT (HR, 0.68 [95% CI, 0.52 to

81 lysis, HAI remained associated with improved OS (HR 0.53, P < 0.002) independent of KRAS status and o

82 ation of XF residential status with improved OS in patients diagnosed not by screening.

83 R was independently associated with improved OS, compared with 50% to 89% and <50% TR.

84 A nominally significant difference in OS in favor of patients randomized to eribulin compared

85 as demonstrated a significant improvement in OS against an active control regimen.

86 ICIs have finally enabled an improvement in OS for patients with SCLC; however, a substantial amount

87 d suggest immunotherapeutic opportunities in OS patients.

88 Analyses included OS, progression-free survival (PFS), and objective respo

89 r overall survival (OS), apart from inferior OS for patients with arterial events (aHR, 1.53; 95% CI,

90 ADT with EBRT plus BT may result in inferior OS compared with EBRT plus ADT in men with intermediate-

91 e characterized by structural defects in IS, OS, and synaptic terminals.

92 t at FUP (P < .001), mean cone density at IS/OS and COST was still lower compared to HFE and ranged b

93 status were lower serum creatinine and KCCQ-OS scores and treatment assignment to MitraClip.

94 OAPT trial were lower serum creatinine, KCCQ-OS score and MitraClip treatment.

95 for HF, or had <5-point improvement in KCCQ-OS at 12 months.

96 to achieve a >=10-point improvement in KCCQ-OS from baseline to 1 month (TMVr, 58%; GDMT alone, 26%)

97 s achieving a >=20-point improvement in KCCQ-OS ranged from 12.5% to 100% and the adjusted median odd

98 inuous variable, a 10-point increase in KCCQ-OS was associated with a 14% lower risk for death or HF

99 Mean KCCQ-OS score was 43.0+/-24.4 at baseline and 67.0+/-24.9 at

100 spitalization and with a 5 to <20-point KCCQ-OS improvement at 12 months.

101 hy Questionnaire overall summary score [KCCQ-OS]) from baseline to 1 month and the composite rate of

102 nforce the prognostic utility of serial KCCQ-OS assessments to identify patients at risk for poor lon

103 myopathy Questionnaire overall summary (KCCQ-OS) score at 12 months.

104 ed RNA-sequencing analysis in JAB1-knockdown OS cells and identified 4110 genes that are significantl

105 score-matched cohort, a significantly longer OS was observed with HER2 blockade (hazard ratio, 0.58;

106 sk scores (PRSs) were associated with longer OS under anti-PD-L1 monotherapy as compared to chemother

107 PyIOmica has been tested on Mac OS X, Unix/Linux and Microsoft Windows.

108 mented in Java and supported on Windows, Mac OS X and Linux.

109 Median OS (mOS) was 3.3 months in the ITT population.

110 Median OS for arm A was 15.5 months (95% CI, 12.2 to 24.3 month

111 Median OS was 13 months (95% CI 10-18) for patients with grade

112 Median OS was 31.15 (95% CI, 20.07 to not reached) and 20.27 mo

113 Median OS was 53 months (1-year OS: 83%, 5-year OS: 43%).

114 Median OS with SIRT, whether or not followed by sorafenib, was

115 nt of early ascites after DEB-TACE-1 (median OS, 17 months), which was closely related to the history

116 Median hemEFS was 19.1 months and median OS had not been reached.

117 7 months (0.03 to >= 9.7 months); and median OS, 25.3 versus 20.8 months for binimetinib and PCC, res

118 In the dose-survival group, median OS was 9.3 months (95% confidence interval [CI]: 6.7 mon

119 s with RAS/TP53 co-mutation had lower median OS: 39 vs. 51 months (P = .02).

120 The median OS for high-risk patients was 78.2 months (95% CI, 62.2

121 h postresection local recurrence, the median OS was 16 months from diagnosis of recurrence (95% CI: 1

122 (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR).

123 The median OS was 64 months with 1-, 3-, 5-, and 10-year OS rates o

124 87% +/- 3%, respectively; P = .019) but not OS (5-year OS +/- SD, 92% +/- 8% and 97% +/- 2%, respect

125 Median (range) refraction OD/OS was +0.88/+1.25 (-8.75 to +4.75/-9.38 to +5.25) spher

126 Although the molecular basis of OS structure remains unresolved, recent studies suggest

127 eveal multiple immunosuppressive features of OS and suggest immunotherapeutic opportunities in OS pat

128 97 postmenopausal women and their levels of OS biomarkers 8-hydroxy-2'-deoxyguanosine (8-OHdG), supe

129 meostasis in the cutaneous manifestations of OS remains to be clarified.

130 h OS and from the Rag2(R229Q) mouse model of OS abundantly express the skin homing receptors cutaneou

131 For parallel NAAT of OS and NPS samples in the second study, McNemar's test i

132 een the frequencies of inconsistent parts of OS and NPS was statistically significant (P = 0.021).

133 s used to identify independent predictors of OS and DFS.

134 [0.48-0.97]) were independent predictors of OS in multivariable analysis, whereas DFS was only adver

135 modeling was used to determine predictors of OS.

136 , but no difference was observed in terms of OS (HR 0.73 (95% CI 0.33-1.63), P = 0.442) and DFS (HR 0

137 role of syntaxin 3 (STX3), in trafficking of OS membrane proteins such as peripherin 2 (PRPH2) and rh

138 ifferences in facial morphology depending on OS levels.

139 eparately but found no significant impact on OS and the risk of relapse.

140 th SR-average disease did not improve CCR or OS, even in patients with higher MRD, in whom it might h

141 mpart in vitro susceptibility only to LAN or OS, respectively.

142 , no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild

143 ly relevant isoprene-derived organosulfates (OSs) with a molecular weight (MW) of 212 (C(5)H(8)SO(7))

144 Osteosarcoma (OS) is the most common primary bone cancer and ranks amo

145 Key secondary end points included overall (OS) and progression-free survival (PFS).

146 s in that cohort, the NAAT results of paired OS and NPS samples from 50 additional recruits with COVI

147 Progression-free survival (PFS), OS, and adverse events were also assessed.

148 operational at the base of the photoreceptor OS where the PCARE module and actin colocalize, but whic

149 as well as its contribution to photoreceptor OS disc morphogenesis, we generated a Prcd-KO animal mod

150 vival (PFS) and overall survival (OS) at PM (OS: hazard ratio [HR], 0.6 and 0.47, respectively; PFS:

151 It had 2 coprimary end points: OS and RFS.

152 l independent prognostic biomarker of poorer OS (HR = 1.27, 95% CI: 1.01, 1.59) and poorer PFS (HR =

153 article size to produce oyster shell powder (OS).

154 inating strength of covariates in predicting OS.

155 osphoric acid (1.6 mM and 3.2 mM) to produce OS + P (oyster shell with phosphoric acid) and COS + P (

156 survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-rece

157 ismatched donors was associated with reduced OS and EFS .

158 osed with invasive breast cancer and refined OS estimates.

159 l cohort at three levels long-term response (OS), the initial response (according to RECIST criteria)

160 asked whether the PRPH2 binding partner rod OS membrane protein 1 (ROM1) could serve as a phenotypic

161 In oriented-sample (OS) solid-state NMR of membrane proteins, the angular-de

162 HAMP common in caterpillar oral secretions (OS).

163 in localized to photoreceptor outer segment (OS) disc membranes.

164 the inner segment (IS) to the outer segment (OS) is critical for photoreceptor function and vision.

165 f rod and cone photoreceptor outer segments (OS).

166 th where responses of orientation selective (OS) GCs were recorded.

167 3.5, 95% CI: 1.3, 12; P = .009) and shorter OS (HR: 3.1; 95% CI: 1.2, 10; P = .02).

168 ive tumours (>=1%) had significantly shorter OS than patients with negative PD-L1 status (p = 0.031).

169 mber (n(C)), average carbon oxidation state (OS C), and volatility (C*).

170 ith occasional renal calcium oxalate stones (OS) and patients with recurrent stones (RS).

171 etime and may cause higher oxidative stress (OS).

172 Critically, in the absence of STX3, OS proteins such as PRPH2, the PRPH2 binding partner, ro

173 M1 are not associated with overall survival (OS) (HR = 1.24, p = 0.47) or time to treatment failure (

174 (HR) 0.32, p < 0.001], and overall survival (OS) [HR 0.45, p = 0.01], and was an independent predicto

175 Median overall survival (OS) after MPE diagnosis was 9 months.

176 n between the 2 groups for overall survival (OS) and disease-free survival (DFS) according to whether

177 Overall survival (OS) and disease-free survival (DFS) were estimated using

178 Primary endpoints were overall survival (OS) and disease-specific survival (DSS).

179 , secondary endpoints were overall survival (OS) and local control (LC).

180 ic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options.

181 tive deaths, 1- and 5-year overall survival (OS) and recurrence-free survival (RFS) were 82%, 57%, an

182 s to improve prognosis for overall survival (OS) and relapse free survival (RFS) outcomes.

183 on-free survival (PFS) and overall survival (OS) at 1, 2, and 3 y.

184 Overall survival (OS) at 12 months was 40% (95% CI, 22%-73%) for patients

185 on-free survival (PFS) and overall survival (OS) at PM (OS: hazard ratio [HR], 0.6 and 0.47, respecti

186 roup patients with similar overall survival (OS) based on clinical T/N stage, tumor grade, ER, PR, HE

187 did not translate into an overall survival (OS) benefit in randomized phase III trials.

188 l (R0) resection rates and overall survival (OS) between the validation patients and PREOPANC patient

189 Overall survival (OS) differed significantly among ELN risk groups, with e

190 as performed using PFS and overall survival (OS) end-points.

191 Primary end point was overall survival (OS) evaluated using adjusted Cox regression analysis.

192 se-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab a

193 LM is associated with poor overall survival (OS) for lung and gastric cancer patients and hence led t

194 However, overall survival (OS) for TERT-low/non-ALT patients was significantly high

195 sensitivity analyses with overall survival (OS) from relapse and Kaplan-Meier statistics.

196 e second randomization and overall survival (OS) from the first or second randomizations.

197 emission, early death, and overall survival (OS) in univariable analyses for each day of treatment de

198 vival (PFS) of >= 9 mo and overall survival (OS) of >= 15 mo as reference.

199 l prognosis, with a median overall survival (OS) of 12-14 months with systemic therapies.

200 ologic characteristics and overall survival (OS) of PDA patients.

201 The overall survival (OS) rates at 1-, 3-, and 5- years from the date of the f

202 on-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85% and 91% for MRD-

203 The 7-year DFS and overall survival (OS) rates were not different as well, with DFS of 66.1%

204 The median overall survival (OS) time for the entire cohort was 126.6 months (95% CI,

205 on-free survival (PFS) and overall survival (OS) times.

206 Median overall survival (OS) was 18 months (95% CI, 8-27); 5-year OS was 18% (95%

207 was 11.8 months and median overall survival (OS) was 25.6 months.

208 p of 4.5 years, the 5-year overall survival (OS) was 91%.

209 was 88.96% +/- 0.46%, and overall survival (OS) was 95.54% +/- 0.31%.

210 progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validatio

211 the primary endpoint, and overall survival (OS) was the secondary endpoint.

212 gression-free survival and overall survival (OS) were 13.9 and 22.3 mo, respectively.

213 -year progression-free and overall survival (OS) were 57% and 71%, respectively (median follow-up, 32

214 tween these parameters and overall survival (OS) were assessed with the Cox proportional hazards mode

215 is-free survival (MFS) and overall survival (OS) were estimated using the Kaplan-Meier method.

216 progression-free (PFS) and overall survival (OS) were evaluated using log-rank tests and Cox proporti

217 ostoperative mortality and overall survival (OS) were similar between sexes.

218 t studies provided data on overall survival (OS) with a pooled HR of 1.91 (95% CI: 1.34, 2.73), indic

219 gh a metaanalysis, whether overall survival (OS) with SIRT, as monotherapy or followed by sorafenib,

220 m from transformation, and overall survival (OS) without statistical comparison between management gr

221 nt-free survival (EFS) and overall survival (OS), and treatment-related mortality (TRM) were compared

222 ion-free survival (PFS) or overall survival (OS), apart from inferior OS for patients with arterial e

223 se-free survival (DFS) and overall survival (OS), estimated using the Kaplan-Meier method and compare

224 ondary end points included overall survival (OS), intracranial progression-free survival (PFS), toxic

225 ional assessments included overall survival (OS), overall response rate (ORR), duration of response (

226 athologic characteristics, overall survival (OS), recurrence-free survival (RFS), and HCC recurrence

227 g-term outcomes, including overall survival (OS), recurrence-free survival (RFS), disease-specific mo

228 ith a primary end point of overall survival (OS), using an alpha of .20 (wherein P < .20 indicates a

229 ers were not predictive of overall survival (OS), which highlighted the challenges of identifying pat

230 se free survival (DFS) and overall survival (OS).

231 nce-free survival (RFS) or overall survival (OS).

232 n-free survival (PFS), and overall survival (OS).

233 tment discontinuation with overall survival (OS).

234 on-free survival (PFS) and overall survival (OS).

235 ecific survival (DSS), and overall survival (OS).

236 and predictors of EFS and overall survival (OS).

237 system best discriminates overall survival (OS).

238 n-free survival (PFS), and overall survival (OS).

239 e free survival (DFS), (v) overall survival (OS).

240 s used to compare bRFS and overall survival (OS).

241 s-free survival (MFS), and overall survival (OS).

242 +/- SE (0.40 +/- 0.01) and overall survival (OS; 0.45 +/- 0.02) were significantly higher with CME co

243 01) and 15 fewer months of overall survival (OS; 95% CI -1 to 31, 92-120 versus 113-129 months, chi2

244 ) and event-free (EFS) and overall survival (OS; secondary end points) were compared with the COG A39

245 The OS and progression-free survival (PFS) of patients with

246 stimate was 87% (95% CI, 79% to 92%) and the OS estimate was 89% (95% CI, 82% to 94%), with iPET-posi

247 hypoxia-responsive proteome profiles in the OS cell phenotypes.

248 A subset of the OS was heated to produce calcined oyster shell (COS).

249 59%) who still have the infection, while the OS test will make such an error in fewer patients (14%).

250 should remain the standard of care, with the OS rate being among the highest reported in the literatu

251 This can be performed through OS or a LS.

252 or >=3 months, benefited most with regard to OS, DFS, and HCC-recurrence (HR: 0.49-0.59, P = 0.0079-0

253 Phaseolus vulgaris), specifically respond to OS via recognition of proteolytic fragments of chloropla

254 With a 2.9-year median follow-up, OS improved from 33% (46-68%) for HCT before 2008 (n = 6

255 The secondary outcomes analyzed here were OS, TTP, and DFS.

256 months; 95% CI: 1.5, 2.9; P = .01), whereas OS was not different (P = .15).

257 f positive depression status were 24.4% (WHI-OS), 25.7% (WHI-HT), and 44.7% (NHSII-MBS).

258 were associated with incident CHD in the WHI-OS; a metabolite score estimated in a Least Absolute Shr

259 baseline, was significantly associated with OS (P < 0.0001), with a C-index of 0.67.

260 SUV(max) were significantly associated with OS (P < 0.005).

261 analyses to be significantly associated with OS and PFS.

262 = 0.001) were significantly associated with OS, whereas PSA values were not (P = 0.059).

263 1.1-7.2) were independently associated with OS.

264 d adjuvant chemotherapy were correlated with OS and DFS.

265 memory/activated T cells from patients with OS and from the Rag2(R229Q) mouse model of OS abundantly

266 Independent predictors of worse OS were primary advanced T category (hazard ratio [HR] 2

267 ollowed by resection had significantly worse OS and PFS than patients receiving first-line chemothera

268 (75th percentile) was associated with worse OS (HR, 2.18; P = 0.037).

269 odes was independently associated with worse OS and DFS (OS: hazard ratio [HR], 0.98; confidence inte

270 R-21 was significantly associated with worse OS in glioma patients; for the other study, which provid

271 ervention or palliative Sorafenib alone (1-y OS of 0%) or Sorafenib with TARE/SBRT (2-y OS of 17%) at

272 y OS of 0%) or Sorafenib with TARE/SBRT (2-y OS of 17%) at our center during the study period.

273 ts without PVTT undergoing upfront LDLT (5-y OS 65%, P = 0.06; RFS 66%, P = 0.33, respectively).

274 Median OS was 53 months (1-year OS: 83%, 5-year OS: 43%).

275 ropensity score-weighted comparison: 10-year OS 89% (95%CI: 81-99%) in SNB only patients vs 86% (95%C

276 S was 64 months with 1-, 3-, 5-, and 10-year OS rates of 89%, 63%, 52%, and 37%, respectively.

277 e 57% and 81%, respectively, and the 10-year OS rates were 29% and 58%, respectively.

278 or comparison purposes, the resultant 2-year OS and PFS rates allowing for that dropout rate were 59.

279 The 2-year OS rates in the control arm are similar to the PACIFIC t

280 tients with double mutation had worse 3-year OS of 18%, compared with 35% without double mutation (P

281 h-risk (>=3 points) groups exhibiting 3-year OS of 78% and 54%, respectively (P = 0.0003).

282 lgamating homogeneous groups based on 3-year OS rates (stage IVA: >50%, stage IVB: 30%-50%, stage IVC

283 to 17.76 at an SSF of 2 showed better 5-year OS (hazard ratio [HR], 0.53 [95% confidence interval {CI

284 y decreased only in the latter group (5-year OS +/- SD in < 18months and >= 18months, 96% +/- 2% and

285 , respectively; P = .019) but not OS (5-year OS +/- SD, 92% +/- 8% and 97% +/- 2%, respectively).

286 mutation status and as predictors of 5-year OS in patients with advanced-stage CRC.Keywords: Abdomen

287 the total number of nodes removed and 5-year OS or DFS was plotted using restricted cubic spline func

288 among ELN risk groups, with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-,

289 The 5-year OS rate was 17.7% in arm 1 (95% CI, 6% to 34%) versus 42

290 al (OS) was 18 months (95% CI, 8-27); 5-year OS was 18% (95% CI, 4%-32%).

291 Perioperative outcomes and 5-year OS were compared.

292 etween radiomics texture features and 5-year OS were determined by using Kaplan-Meier estimators usin

293 with IME (5-year EFS, 0.33 +/- 0.03; 5-year OS, 0.37 +/- 0.03; P < .001 and P = .004).

294 ian OS was 53 months (1-year OS: 83%, 5-year OS: 43%).

295 The 6-year OS rate for > 5,000 children with SR ALL enrolled in AAL

296 Five-year OS rates for high-risk and standard-risk patients were 5

297 Five-year OS rates were 39% with nivolumab and 17% with dacarbazin

298 Five-year OS was 38% in patients randomly assigned to dacarbazine

299 Five-year OS was consistently worse at local LVH and IVH.

300 Three-year OS was 55.5% (95% confidence interval, 40.8-68.0).